Back to Search Start Over

Melatonin and agomelatine for preventing seasonal affective disorder.

Authors :
Nussbaumer-Streit, Barbara
Nussbaumer-Streit, Barbara
Greenblatt, Amy
Kaminski-Hartenthaler, Angela
Van Noord, Megan G
Forneris, Catherine A
Morgan, Laura C
Gaynes, Bradley N
Wipplinger, Jörg
Lux, Linda J
Winkler, Dietmar
Gartlehner, Gerald
Nussbaumer-Streit, Barbara
Nussbaumer-Streit, Barbara
Greenblatt, Amy
Kaminski-Hartenthaler, Angela
Van Noord, Megan G
Forneris, Catherine A
Morgan, Laura C
Gaynes, Bradley N
Wipplinger, Jörg
Lux, Linda J
Winkler, Dietmar
Gartlehner, Gerald
Source :
The Cochrane database of systematic reviews; vol 6, iss 6, CD011271; 1469-493X
Publication Year :
2019

Abstract

BackgroundSeasonal affective disorder (SAD) is a seasonal pattern of recurrent major depressive episodes that most commonly starts in autumn or winter and remits in spring. The prevalence of SAD depends on latitude and ranges from 1.5% to 9%. The predictable seasonal aspect of SAD provides a promising opportunity for prevention in people who have a history of SAD. This is one of four reviews on the efficacy and safety of interventions to prevent SAD; we focus on agomelatine and melatonin as preventive interventions.ObjectivesTo assess the efficacy and safety of agomelatine and melatonin (in comparison with each other, placebo, second-generation antidepressants, light therapy, psychological therapy or lifestyle interventions) in preventing SAD and improving person-centred outcomes among adults with a history of SAD.Search methodsWe searched Ovid MEDLINE (1950- ), Embase (1974- ), PsycINFO (1967- ) and the Cochrane Central Register of Controlled Trials (CENTRAL) to 19 June 2018. An earlier search of these databases was conducted via the Cochrane Common Mental Disorders Controlled Trial Register (CCMD-CTR) (all years to 11 August 2015). Furthermore, we searched the Cumulative Index to Nursing and Allied Health Literature, Web of Science, the Cochrane Library, the Allied and Complementary Medicine Database and international trial registers (to 19 June 2018). We also conducted a grey literature search and handsearched the reference lists of included studies and pertinent review articles.Selection criteriaTo examine efficacy, we included randomised controlled trials (RCTs) on adults with a history of winter-type SAD who were free of symptoms at the beginning of the study. For adverse events, we intended also to include non-randomised studies. We planned to include studies that compared agomelatine versus melatonin, or agomelatine or melatonin versus placebo, any second-generation antidepressant, light therapy, psychological therapies or lifestyle changes. We also intended

Details

Database :
OAIster
Journal :
The Cochrane database of systematic reviews; vol 6, iss 6, CD011271; 1469-493X
Notes :
application/pdf, The Cochrane database of systematic reviews vol 6, iss 6, CD011271 1469-493X
Publication Type :
Electronic Resource
Accession number :
edsoai.on1391599049
Document Type :
Electronic Resource